Novo Nordisk's Ozempic successor disappointed Wall Street again
Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...
Even your weight loss drugs aren't safe from tariffs
Novo Nordisk (NVO), the maker of the popular diabetes and weight-loss drugs Ozempic and Wegovy, expects at least some short-term impacts from President Donald Trump’s proposed tariffs.